Kristie L. Kahl is vice president of content at MJH Life Sciences, overseeing CURE®, CancerNetwork®, the journal ONCOLOGY, Targeted Oncology, and Urology Times®. She has been with the company since November 2017.
She is a graduate of Rider University, where she acquired a Bachelors of Art in journalism, as well as a graduate of Temple University, where she received her Masters of Science in Sports Management.
Follow Kristie on Twitter at @KristieLKahl, or email her at kkahl@mjhlifesciences.com.
Educated Patient® Breast Cancer Summit at MBCC HER2-Positive Disease Panel: March 4, 2023
March 2nd 2023Watch Dr. Naomi Dempsey, Dr. Ana Sandoval Leon, Dr. Rupesh Kotecha and Ricki Fairley answer questions about HER2-positive disease during the CURE Educated Patient® Breast Cancer Summit at MBCC.
Read More
Educated Patient® Multiple Myeloma Summit Treating Myeloma Long-Term Panel: November 13, 2022
December 6th 2022Watch Valarie Traynham, of the HealthTree Foundation, discuss the long-term journey of the disease and disparities still seen during the CURE® Educated Patient® Multiple Myeloma Summit.
Read More
‘Planning Your Next Shot’ In the Prostate Cancer Continuum With Patient-Physician Communication
October 6th 2022As part of its Speaking Out video series, on behalf of Fans for the Cure, CURE® spoke with Tony Crispino about the importance of patient-physician communication in prostate cancer.
Read More
Patients Can Help Move the Needle Forward in Bladder Cancer Clinical Trials With Participation
September 29th 2022As part of its “Speaking Out” video series, CURE spoke with Dr. Tracy L. Rose, on behalf of the Bladder Cancer Advocacy Network, about how patients can find clinical trials they may be eligible for.
Read More
Combining Old and New Therapies in Advanced Bladder Cancer Shows Promise for the Future
September 29th 2022As part of its “Speaking Out” video series, CURE spoke with Dr. Tracy L. Rose, on behalf of the Bladder Cancer Advocacy Network, about how currently available agents are being investigated in combination with one another.
Read More
Longer Hormone Therapy After Main Treatments Delays Prostate Cancer Metastasis
September 13th 2022Two years of the hormone treatment androgen-deprivation therapy (ADT) after radiotherapy and radical prostatectomy tended to improve metastasis-free survival for patients with prostate cancer, study results showed.
Read More
Adding Cabometyx to Immunotherapy Combination Improves Outcomes for Advanced Kidney Cancer
September 12th 2022The addition of Cabometyx to the current standard-of-care frontline regimen of Opdivo plus Yervoy improved progression-free survival outcomes in patients with advanced kidney cancer.
Read More